Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBP11
- Development stage
- Phase 2
- Lead developer
- Entera Bio
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
EBP11 is an investigational oral drug formulation developed by Entera Bio. Its mechanism of action is currently unknown, and it does not represent a novel mechanism. EBP11 has been studied as a modified oral formulation in clinical trials comparing the pharmacokinetics of human parathyroid hormone (hPTH 1-34) with other formulations such as EBP22, EBP05, and subcutaneous Forteo. The primary indications under investigation include osteoporosis and hypoparathyroidism[1][4]. As of now, there are no approved indications or known adverse events associated with this drug.
- Other names
- Long Acting PTHPTH-CTP
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on EBP11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBP11.